Barr Patent Challenge Expenses Estimated At $200 Mil. Over Next Five Years
Executive Summary
Barr expects to spend about $200 mil. in Paragraph IV patent challenges through 2007, CEO Bruce Downey told a recent Generic Pharmaceutical Association workshop in New York City
You may also be interested in...
AstraZeneca Prilosec Patent Litigation Decision By Mid-Year, Andrx Says
Andrx expects a decision regarding AstraZeneca's Prilosec (omeprazole) patent litigation by mid-year
Barr Generic Ortho-Novum 7/7/7 To Launch Nine Months Prior To Patent Expiry
Barr will launch Nortrel 7/7/7, its generic of Ortho-McNeil's Ortho-Novum 7/7/7, in January 2003 per an Oct. 29 patent litigation settlement
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011